Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma (original) (raw)

• Guarente L. The many faces of sirtuins: sirtuins and the Warburg effect. Nat Med. 2014;20:24–25.
  Article CAS PubMed Google Scholar
• Chen Y, Fu LL, Wen X, et al. Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer. Cell Death Dis. 2014;5:e1047.
  Article CAS PubMed PubMed Central Google Scholar
• Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest. 2009;119:2758–2771.
  CAS PubMed PubMed Central Google Scholar
• Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. Sirtuin-3 (SIRT3) and the hallmarks of cancer. Genes Cancer. 2013;4:164–171.
  Article PubMed PubMed Central Google Scholar
• Cho EH. SIRT3 as a regulator of non-alcoholic fatty liver disease. J Lifestyle Med. 2014;4:80–85.
  Article PubMed PubMed Central Google Scholar
• Teodoro JS, Duarte FV, Gomes AP, et al. Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: a possible role for SirT3 activation. Mitochondrion. 2013;13:637–646.
  Article CAS PubMed Google Scholar
• Choudhury M, Jonscher KR, Friedman JE. Reduced mitochondrial function in obesity-associated fatty liver: SIRT3 takes on the fat. Aging (Albany NY). 2011;3:175–178.
  Article CAS Google Scholar
• Stroffolini T, Trevisani F, Pinzello G, et al. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Dig Liver Dis. 2011;43:875–880.
  Article PubMed Google Scholar
• Faloppi L, Scartozzi M, Maccaroni E, et al. Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev. 2011;37:169–177.
  Article CAS PubMed Google Scholar
• Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol. 2015;21:12003–12021.
  Article CAS PubMed PubMed Central Google Scholar
• Weir HJ, Lane JD, Balthasar N. SIRT3: a central regulator of mitochondrial adaptation in health and disease. Genes Cancer. 2013;4:118–124.
  Article CAS PubMed PubMed Central Google Scholar
• Guarente L, Kenyon C. Genetic pathways that regulate ageing in model organisms. Nature. 2000;408:255–262.
  Article CAS PubMed Google Scholar
• Dhillon RS, Denu JM. Using comparative biology to understand how aging affects mitochondrial metabolism. Mol Cell Endocrinol. 2016. doi:10.1016/j.mce.2016.12.020.
  Google Scholar
• Kim HS, Patel K, Muldoon-Jacobs K, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell. 2010;17:41–52.
  Article CAS PubMed PubMed Central Google Scholar
• Shi T, Wang F, Stieren E, Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem. 2005;280:13560–13567.
  Article CAS PubMed Google Scholar
• Sack MN, Finkel T. Mitochondrial metabolism, sirtuins, and aging. Cold Spring Harb Perspect Biol. 2012;4:a013102. doi:10.1101/cshperspect.a013102.
• Ansari A, Rahman MS, Saha SK, Saikot FK, Deep A, Kim KH. Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease. Aging Cell. 2017;16:4–16.
  Article CAS PubMed Google Scholar
• Carafa V, Nebbioso A, Altucci L. Sirtuins and disease: the road ahead. Front Pharmacol. 2012;31:3–4.
  Google Scholar
• Nogueiras R, Habegger KM, Chaudhary N, et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012;92:1479–1514.
  Article CAS PubMed PubMed Central Google Scholar
• Hebert AS, Dittenhafer-Reed KE, Yu W, et al. Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. Mol Cell. 2013;49:186–199.
  Article CAS PubMed Google Scholar
• Hirschey M, Shimazu T, Goetzman E, et al. SIRT3 regulates mitochondrial fatty acid oxidation via reversible enzyme deacetylation. Nature. 2010;464:121–125.
  Article CAS PubMed PubMed Central Google Scholar
• Buler M, Aatsinki SM, Izzi V, Hakkola J. Metformin reduces hepatic expression of SIRT3, the mitochondrial deacetylase controlling energy metabolism. PLoS ONE. 2012;7:e49863.
  Article CAS PubMed PubMed Central Google Scholar
• Hirschey M, Shimazu T, Jing E, et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell. 2011;44:177–190.
  Article CAS PubMed PubMed Central Google Scholar
• He J, Hu B, Shi X, et al. Activation of the aryl hydrocarbon receptor sensitizes mice to nonalcoholic steatohepatitis by deactivating mitochondrial sirtuin deacetylase Sirt3. Mol Cell Biol. 2013;33:2047–2055.
  Article CAS PubMed PubMed Central Google Scholar
• Souza MR, Diniz F, Medeiros-Filho JE, Araújo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 2012;49:89–96.
  Article PubMed Google Scholar
• Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972–1978.
  Article PubMed Google Scholar
• Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32–42.
  Article CAS PubMed Google Scholar
• Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013;62:606–615.
  Article CAS PubMed Google Scholar
• Chen TM, Lin CC, Huang PT, Wen CF. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2011;26:858–865.
  Article PubMed Google Scholar
• Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108:881–891.
  Article CAS PubMed Google Scholar
• Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010;30:750–758.
  Article CAS PubMed Google Scholar
• Tao R, Coleman MC, Pennington JD, et al. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell. 2010;40:893–904.
  Article CAS PubMed PubMed Central Google Scholar
• Finley LW, Carracedo A, Lee J, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell. 2011;19:416–442.
  Article CAS PubMed PubMed Central Google Scholar
• Schumacker PT. SIRT3 controls cancer metabolic reprogramming by regulating ROS and HIF. Cancer Cell. 2011;19:299–300.
  Article CAS PubMed PubMed Central Google Scholar
• Koyama T, Kume S, Koya D, et al. SIRT3 attenuates palmitate-induced ROS production and inflammation in proximal tubular cells. Free Radic Bio Med. 2011;51:1258–1267.
  Article CAS Google Scholar
• Alhazzazi TY, Kamarajan P, Joo N, et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer. 2011;117:1670–1678.
  Article CAS PubMed Google Scholar
• Lai CC, Lin PM, Lin SF, et al. Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biol. 2013;34:1847–1854.
  Article CAS PubMed Google Scholar
• George J, Nihal M, Singh CK, Zhong W, Liu X, Ahmad N. Pro-proliferative function of mitochondrial sirtuin deacetylase SIRT3 in human melanoma. J Invest Dermatol. 2016;136:809–818.
  Article CAS PubMed Google Scholar
• Choi J, Koh E, Lee YS, et al. Mitochondrial Sirt3 supports cell proliferation by regulating glutamine-dependent oxidation in renal cell carcinoma. Biochem Biophys Res Commun. 2016;474:547–553.
  Article CAS PubMed Google Scholar
• Zhang L, Ren X, Cheng Y, et al. Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells. Biochem Pharmacol. 2013;86:726–733.
  Article CAS PubMed Google Scholar
• Xiang XY, Kang JS, Yang XC, et al. SIRT3 participates in glucose metabolism interruption and apoptosis induced by BH3 mimetic S1 in ovarian cancer cells. Int J Oncol. 2016;49:773–784.
  CAS PubMed Google Scholar
• Li H, Feng Z, Wu W, Li J, Zhang J, Xia T. SIRT3 regulates cell proliferation and apoptosis related to energy metabolism in non-small cell lung cancer cells through deacetylation of NMNAT2. Int J Oncol. 2013;43:1420–1430.
  CAS PubMed PubMed Central Google Scholar
• Xiao K, Jiang J, Wang W, et al. Sirt3 is a tumor suppressor in lung adenocarcinoma cells. Oncol Rep. 2013;30:1323–1328.
  CAS PubMed Google Scholar
• Allison SJ, Milner J. SIRT3 is pro-apoptotic and participates in distinct basal apoptotic pathways. Cell Cycle. 2007;6:2669–2677.
  Article CAS PubMed Google Scholar
• Liu C, Huang Z, Jiang H, Shi F. The sirtuin 3 expression profile is associated with pathological and clinical outcomes in colon cancer patients. Biomed Res Int. 2014;2014:871263.
  PubMed PubMed Central Google Scholar
• Yang B, Fu X, Shao L, Ding Y, Zeng D. Aberrant expression of SIRT3 is conversely correlated with the progression and prognosis of human gastric cancer. Biochem Biophys Res Commun. 2014;443:156–160.
  Article CAS PubMed Google Scholar
• Wang L, Wang WY, Cao LP. SIRT3 inhibits cell proliferation in human gastric cancer through down-regulation of Notch-1. Int J Clin Exp Med. 2015;8:5263–5271.
  CAS PubMed PubMed Central Google Scholar
• Marfe G, Tafani M, Indelicato M, et al. Kaempferol induces apoptosis in two different cell lines via Akt inactivation, Bax and SIRT3 activation, and mitochondrial dysfunction. J Cell Biochem. 2009;106:643–650.
  Article CAS PubMed Google Scholar
• Yu W, Denu RA, Krautkramer KA, et al. Loss of SIRT3 provides growth advantage for B cell malignancies. J Biol Chem. 2016;291:3268–3279.
  Article CAS PubMed Google Scholar
• Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem. 2005;16:449–466.
  Article CAS PubMed Google Scholar
• Faccioruso A, Villani R, Bellanti F, Mitarotonda D, Vendemiale G, Serviddio G. Mitochondrial signaling and hepatocellular carcinoma: molecular mechanisms and therapeutic implications. Curr Pharm Des. 2016;22:2689–2696.
  Article Google Scholar
• Yoon CY, Park MJ, Lee JS, et al. The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line. J Urol. 2001;185:1102–1111.
  Article Google Scholar
• Royce SG, Dang W, Yuan G, et al. Effects of the histone deacetylase inhibitor, trichostatin A, in a chronic allergic airways disease model in mice. Arch Immunol Ther Exp. 2012;60:295–306.
  Article CAS Google Scholar
• Wang JX, Yi Y, Li YW, et al. Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection. BMC Cancer. 2014;14:297.
  Article CAS PubMed PubMed Central Google Scholar
• Casaril M, Corso F, Bassi A, Nicoli N, Bellisola G, Corrocher R. Decreased activity of scavenger enzymes in human hepatocellular carcinoma, but not in liver metastases. Int J Clin Lab Res. 1994;24:94–97.
  Article CAS PubMed Google Scholar
• Liaw KY, Lee PH, Wu FC, Tsai JS, Lin-Shiau SY. Zinc, copper, and superoxide dismutase in hepatocellular carcinoma. Am J Gastroenterol. 1997;92:2260–2263.
  CAS PubMed Google Scholar
• Fabregat I, Roncero C, Fernández M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int. 2007;27:155–162.
  Article CAS PubMed Google Scholar
• Song CL, Tang H, Ran LK, et al. Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3β/BCL2-associated X protein-dependent apoptotic pathway. Oncogene. 2016;35:631–641.
  Article CAS PubMed Google Scholar
• Zhang CZ, Liu L, Cai M, et al. Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS ONE. 2012;7:e51703.
  Article CAS PubMed PubMed Central Google Scholar
• Ren JH, Chen X, Zhou L, et al. Protective role of Sirtuin3 (SIRT3) in oxidative stress mediated by hepatitis B virus X protein expression. PLoS ONE. 2016;11:e0150961.
  Article PubMed PubMed Central Google Scholar
• Zhang YY, Zhou LM. Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation. Biochem Biophys Res Commun. 2012;423:26–31.
  Article CAS PubMed Google Scholar
• Tao NN, Zhou HZ, Tang H, et al. Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway. Oncotarget. 2016. doi:10.18632/oncotarget.10319.
  Google Scholar
• Abdul NA, Nagiah S, Chuturgoon AA. Fusaric acid induces mitochondrial stress in human hepatocellular carcinoma (HepG2) cells. Toxicon. 2016;119:336–344.
  Article Google Scholar
• Li Y, Wang W, Xu X, Sun S, Xu X, Qu XJ. {2-[1-(3-Methoxycarbonylmethyl-1H-indol-2-yl)-1-methyl-ethyl]-1H-indol-3-yl}-acetic acid methyl ester (MIAM) inhibited human hepatocellular carcinoma growth through upregulation of Sirtuin-3 (SIRT3). Biomed Pharmacother. 2015;69:125–132.
  Article CAS PubMed Google Scholar
• Li Y, Wang W, Xu X, Sun S, Xu X, Qu XJ. {2-[1-(3-Methoxycarbonylmethyl-1H-indol-2-yl)-1-methyl-ethyl]-1H-indol-3-yl}-acetic acid methyl ester inhibited hepatocellular carcinoma growth in bel-7402 cells and its resistant variants by activation of NOX4 and SIRT3. Biomed Res Int. 2015;2015:491205.
  PubMed PubMed Central Google Scholar